Efficacy and Safety of Favipiravir in Moderate COVID-19 Pneumonia Patients without Oxygen Therapy: A Randomized, Phase III Clinical Trial

被引：0

作者：

Masaharu Shinkai

Kenji Tsushima

Shingo Tanaka

Eri Hagiwara

Norihito Tarumoto

Ichiro Kawada

Yuji Hirai

Sho Fujiwara

Yuko Komase

Takeshi Saraya

Hidefumi Koh

Naho Kagiyama

Megumi Shimada

Daiki Kanou

Shinichi Antoku

Yujiro Uchida

Yutaka Tokue

Mikio Takamori

Yasuhiro Gon

Kenya Ie

Yoshitaka Yamazaki

Kazumasa Harada

Naoki Miyao

Takashi Naka

Mitsunaga Iwata

Atsushi Nakagawa

Kazutoshi Hiyama

Yoshihiko Ogawa

Masahiro Shinoda

Shinichiro Ota

Takatomo Hirouchi

Jiro Terada

Shuichi Kawano

Takashi Ogura

Tsutomu Sakurai

Yoshihiko Matsumoto

Hiroyuki Kunishima

Osamu Kobayashi

Satoshi Iwata

机构：

[1] Tokyo Shinagawa Hospital,Department of Respiratory Medicine

[2] International University of Health and Welfare,Department of Pulmonary Medicine, School of Medicine

[3] Self-Defense Forces Central Hospital,Department of Otolaryngology

[4] Kanagawa Cardiovascular and Respiratory Center,Department of Respiratory Medicine

[5] Saitama Medical University Hospital,Department of Infectious Disease and Infection control

[6] Keio University,Division of Pulmonary Medicine, Department of Medicine, School of Medicine

[7] Tokyo Medical University Hachioji Medical Center,Department of Infectious Diseases

[8] Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital,Department of Infectious Diseases

[9] St. Marianna University Yokohama City Seibu Hospital,Department of Respiratory Internal Medicine

[10] Kyorin University School of Medicine,Department of Respiratory Medicine

[11] Tachikawa Hospital,Division of Pulmonary Medicine, Department of Internal Medicine

[12] Saitama Cardiovascular and Respiratory Center,Department of Respiratory Medicine

[13] Tokai University Oiso Hospital,Department of General Internal Medicine

[14] Yokohama Rosai Hospital,Department of Respiratory Internal Medicine

[15] Edogawa Hospital,Department of Diabetes, Metabolism and Kidney Disease

[16] Kitakyushu Municipal Medical Center,Department of General Medicine

[17] Gunma University Hospital,Infection Control and Prevention Center

[18] Tokyo Metropolitan Tama Medical Center,Department of Respiratory Medicine

[19] Nihon University Itabashi Hospital,Department of Respiratory Medicine

[20] Kawasaki Municipal Tama Hospital,Department of General Internal Medicine

[21] Nagano Prefectural Shinshu Medical Center,Department of Respiratory and Infectious Diseases

[22] Tokyo Metropolitan Geriatric Hospital and Institute of Gerontology,Department of Cardiology

[23] Nippon Koukan Hospital,Department of Internal Medicine

[24] Higashiosaka City Medical Center,Department of Neurology

[25] Fujita Health University Hospital,Department of Emergency and General Internal Medicine

[26] Kobe City Medical Center General Hospital,Department of Respiratory Medicine

[27] National Hospital Organization Fukuokahigashi Medical Center,Department of Infectious Diseases

[28] Sakai City Medical Center,Department of Infectious Diseases

[29] Self-Defense Forces Central Hospital,Department of Internal Medicine

[30] FujiFilm Toyama Chemical Co.,Scientific Information Department

[31] Ltd.,Department of Infectious Diseases, School of Medicine

[32] St. Marianna University,Department of Infectious Diseases

[33] National Cancer Center Hospital,undefined

来源：

Infectious Diseases and Therapy | 2021年 / 10卷

关键词：

COVID-19; Favipiravir; Oral antiviral agent; Phase III clinical trial; Moderate pneumonia not requiring oxygen therapy; SARS-CoV-2; Treatment efficacy;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：2489 / 2509

页数：20

共 62 条

[1]

Gowen BB(2007)In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections Antimicrob Agents Chemother 51 3168-3176

[2]

Wong MH(2011)Effective oral favipiravir (T-705) therapy initiated after the onset of clinical disease in a model of arenavirus hemorrhagic fever PLoS Negl Trop Dis 5 e1342-271

[3]

Jung KH(2020)Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro Cell Res 30 269-6797

[4]

Mendenhall M(2020)Rapid incorporation of favipiravir by the fast and permissive viral RNA polymerase complex results in SARS-CoV-2 lethal mutagenesis Nat Commun 11 4682-1198

[5]

Russell A(2020)Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency J Biol Chem 295 6785-851

[6]

Smee DF(2020)Experimental treatment with favipiravir for COVID-19: An open-label control study Eng (Beijing) 6 1192-857

[7]

Wang M(2007)Efficacy of orally administered T-705 on lethal avian influenza A (H5N1) virus infections in mice Antimicrob Agents Chemother 51 845-37

[8]

Cao R(2021)A multicenter non-randomized, uncontrolled single arm trial for evaluation of the efficacy and the safety of the treatment with favipiravir for patients with severe fever with thrombocytopenia syndrome PLoS Negl Trop Dis 22 e0009103-71

[9]

Zhang L(1999)Modification of sample size in group sequential clinical trials Biometrics 55 853-26965

[10]

Shanon A(2021)Clinical features of 154 COVID-19 patients and parameters for effective detection of pneumonia at the time of initial diagnosis in Japan Intern Med 60 31-7

← 1 2 3 4 5 6 7 →